Literature DB >> 27698434

In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study.

S E Holmes1, R Hinz2, R J Drake3, C J Gregory1, S Conen1, J C Matthews2, J M Anton-Rodriguez2, A Gerhard1, P S Talbot1.   

Abstract

Positron emission tomography (PET) imaging of the 18 kDa translocator protein (TSPO) has been used to investigate whether microglial activation, an indication of neuroinflammation, is evident in the brain of adults with schizophrenia. Interpretation of these studies is confounded by potential modulatory effects of antipsychotic medication on microglial activity. In the first such study in antipsychotic-free schizophrenia, we have used [11C](R)-PK11195 PET to compare TSPO availability in a predominantly antipsychotic-naive group of moderate-to-severely symptomatic unmedicated patients (n=8), similarly symptomatic medicated patients with schizophrenia taking risperidone or paliperidone by regular intramuscular injection (n=8), and healthy comparison subjects (n=16). We found no evidence for increased TSPO availability in antipsychotic-free patients compared with healthy controls (mean difference 4%, P=0.981). However, TSPO availability was significantly elevated in medicated patients (mean increase 88%, P=0.032) across prefrontal (dorsolateral, ventrolateral, orbital), anterior cingulate and parietal cortical regions. In the patients, TSPO availability was also strongly correlated with negative symptoms measured using the Positive and Negative Syndrome Scale across all the brain regions investigated (r=0.651-0.741). We conclude that the pathophysiology of schizophrenia is not associated with microglial activation in the 2-6 year period following diagnosis. The elevation in the medicated patients may be a direct effect of the antipsychotic, although this study cannot exclude treatment resistance and/or longer illness duration as potential explanations. It also remains to be determined whether it is present only in a subset of patients, represents a pro- or anti-inflammatory state, its association with primary negative symptoms, and whether there are significant differences between antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27698434     DOI: 10.1038/mp.2016.180

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  70 in total

1.  The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys.

Authors:  Karl-Anton Dorph-Petersen; Joseph N Pierri; James M Perel; Zhuoxin Sun; Allan R Sampson; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2005-09       Impact factor: 7.853

2.  Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.

Authors:  Rikus Knegtering; Pepijn Baselmans; Stynke Castelein; Fokko Bosker; Richard Bruggeman; Robert J van den Bosch
Journal:  Am J Psychiatry       Date:  2005-05       Impact factor: 18.112

3.  Evaluation of reference regions for (R)-[(11)C]PK11195 studies in Alzheimer's disease and mild cognitive impairment.

Authors:  Marc A Kropholler; Ronald Boellaard; Bart N M van Berckel; Alie Schuitemaker; Reina W Kloet; Mark J Lubberink; Cees Jonker; Philip Scheltens; Adriaan A Lammertsma
Journal:  J Cereb Blood Flow Metab       Date:  2007-04-04       Impact factor: 6.200

4.  Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest.

Authors:  Ioannis S Gousias; Daniel Rueckert; Rolf A Heckemann; Leigh E Dyet; James P Boardman; A David Edwards; Alexander Hammers
Journal:  Neuroimage       Date:  2007-12-03       Impact factor: 6.556

5.  Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA.

Authors:  Miran Kenk; Thiviya Selvanathan; Naren Rao; Ivonne Suridjan; Pablo Rusjan; Gary Remington; Jeffrey H Meyer; Alan A Wilson; Sylvain Houle; Romina Mizrahi
Journal:  Schizophr Bull       Date:  2014-11-09       Impact factor: 9.306

6.  Common variants on chromosome 6p22.1 are associated with schizophrenia.

Authors:  Jianxin Shi; Douglas F Levinson; Jubao Duan; Alan R Sanders; Yonglan Zheng; Itsik Pe'er; Frank Dudbridge; Peter A Holmans; Alice S Whittemore; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Raymond R Crowe; Jorge R Oksenberg; Daniel B Mirel; Kenneth S Kendler; Robert Freedman; Pablo V Gejman
Journal:  Nature       Date:  2009-07-01       Impact factor: 49.962

7.  Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Lian Yuan Cao; Pei Yan Zhang; Gui Ying Wu; Yu Cun Shen
Journal:  J Clin Psychiatry       Date:  2004-07       Impact factor: 4.384

8.  The 18-kDa mitochondrial translocator protein in human gliomas: an 11C-(R)PK11195 PET imaging and neuropathology study.

Authors:  Zhangjie Su; Federico Roncaroli; Pascal F Durrenberger; David J Coope; Konstantina Karabatsou; Rainer Hinz; Gerard Thompson; Federico E Turkheimer; Karolina Janczar; Daniel Du Plessis; Andrew Brodbelt; Alan Jackson; Alexander Gerhard; Karl Herholz
Journal:  J Nucl Med       Date:  2015-02-26       Impact factor: 10.057

9.  Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies.

Authors:  P Fusar-Poli; R Smieskova; M J Kempton; B C Ho; N C Andreasen; S Borgwardt
Journal:  Neurosci Biobehav Rev       Date:  2013-06-14       Impact factor: 8.989

10.  In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma.

Authors:  J M Coughlin; Y Wang; E B Ambinder; R E Ward; I Minn; M Vranesic; P K Kim; C N Ford; C Higgs; L N Hayes; D J Schretlen; R F Dannals; M Kassiou; A Sawa; M G Pomper
Journal:  Transl Psychiatry       Date:  2016-04-12       Impact factor: 6.222

View more
  35 in total

1.  Linking Cortical and Connectional Pathology in Schizophrenia.

Authors:  Maria Angelique Di Biase; Vanessa L Cropley; Luca Cocchi; Alexander Fornito; Fernando Calamante; Eleni P Ganella; Christos Pantelis; Andrew Zalesky
Journal:  Schizophr Bull       Date:  2019-06-18       Impact factor: 9.306

Review 2.  Psychosis: an autoimmune disease?

Authors:  Adam A J Al-Diwani; Thomas A Pollak; Sarosh R Irani; Belinda R Lennox
Journal:  Immunology       Date:  2017-08-03       Impact factor: 7.397

3.  Microglia and schizophrenia: where next?

Authors:  T Notter; U Meyer
Journal:  Mol Psychiatry       Date:  2017-03-28       Impact factor: 15.992

4.  Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia.

Authors:  T Notter; J M Coughlin; T Gschwind; U Weber-Stadlbauer; Y Wang; M Kassiou; A C Vernon; D Benke; M G Pomper; A Sawa; U Meyer
Journal:  Mol Psychiatry       Date:  2017-01-17       Impact factor: 15.992

Review 5.  Sifting through the surfeit of neuroinflammation tracers.

Authors:  Paul Cumming; Bjorn Burgher; Omkar Patkar; Michael Breakspear; Neil Vasdev; Paul Thomas; Guo-Jun Liu; Richard Banati
Journal:  J Cereb Blood Flow Metab       Date:  2017-12-19       Impact factor: 6.200

6.  Translocator protein (TSPO) and stress cascades in mouse models of psychosis with inflammatory disturbances.

Authors:  Daisuke Fukudome; Lindsay N Hayes; Travis E Faust; Catherine A Foss; Mari A Kondo; Brian J Lee; Atsushi Saito; Shin-Ichi Kano; Jennifer M Coughlin; Atsushi Kamiya; Martin G Pomper; Akira Sawa; Minae Niwa
Journal:  Schizophr Res       Date:  2018-02-03       Impact factor: 4.939

7.  TSPO expression and brain structure in the psychosis spectrum.

Authors:  Sina Hafizi; Elisa Guma; Alex Koppel; Tania Da Silva; Michael Kiang; Sylvain Houle; Alan A Wilson; Pablo M Rusjan; M Mallar Chakravarty; Romina Mizrahi
Journal:  Brain Behav Immun       Date:  2018-06-12       Impact factor: 7.217

8.  Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.

Authors:  Shima Shakory; Jeremy J Watts; Sina Hafizi; Tania Da Silva; Saad Khan; Michael Kiang; R Michael Bagby; Sofia Chavez; Romina Mizrahi
Journal:  Neuropsychopharmacology       Date:  2018-07-28       Impact factor: 7.853

Review 9.  Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System.

Authors:  Ayushi Anna Dinesh; Juned Islam; Javad Khan; Federico Turkheimer; Anthony C Vernon
Journal:  CNS Drugs       Date:  2020-09-25       Impact factor: 5.749

10.  GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study.

Authors:  Tania Da Silva; Sina Hafizi; Pablo M Rusjan; Sylvain Houle; Alan A Wilson; Ivana Prce; Napapon Sailasuta; Romina Mizrahi
Journal:  J Psychiatry Neurosci       Date:  2019-03-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.